
STIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months
CEO Neil Warma describes ProMIS's approach of targeting amyloid beta oligomers as opposed to the plaques. He explains how so far they have avoided the ARIA (brain swelling) seen with other Alzheimer's treatments and discusses what the company hopes to see from this phase 1b study. Plus, comments on the recent failure of another company in this space.
Publisher
BiotechTV - News
Link
podcasters.spotify.com/pod/show/biotechtv4/episodes/STIFEL-2026-ProMIS-Neurosciences-has-an-early--yet-important-Alzheimers-trial-scheduled-to-read-out-over-the-coming-months-e3s7s29
Published
November 11, 2026
Duration
19 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
Host
BiotechTV
BiotechTV - News
@biotechtvnews
#promisneurosciences #yetimportantalzheimers #comingmonths #lifesciences
